Cryoport, Inc.(CYRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,539 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in CYRX
Events flagged as statistical outliers against CYRX's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
CYRX quality score dropped 27 points (60→32) on a new filing
View source filing →
CYRX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Cryoport, Inc. (CYRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CYRX at 29.0/100 on a 32-signal composite quality model, placing it at rank #2,539 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (14.6) and free cash flow (16.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cryoport, Inc. reports quarterly revenue of $49.0M, net income of $-8.3M, an operating margin of -20.5%. Top institutional holders of CYRX by reported 13-F value include BlackRock, CADIAN CAPITAL MANAGEMENT, MORGAN STANLEY, based on the most recent SEC filings. CYRX trades on the Nasdaq exchange and files with the SEC under CIK 1124524. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CYRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cryoport, Inc. directly from SEC EDGAR. Cryoport, Inc.'s 13F Pro composite quality score has ranged between 17 and 50 since 2021, currently 29.0 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$49.0M
Net Income
Q2 2026
$-8.3M
Free Cash Flow
Q2 2026
$-8.0M
Operating Margin
Q2 2026
-20.5%
ROIC
Q2 2026
-8.2%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+12.4% YoYNet Income
+168.2% YoYOperating Income
+69.7% YoYEPS (Diluted)
+156.2% YoYTotal Assets
+8.7% YoYOp. Cash Flow
+47.4% YoYFree Cash Flow
+25.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $176.2M +12.4% | $156.8M -7.1% | $168.7M -28.9% | $237.3M +6.6% | $222.6M +182.9% | $78.7M |
| Net Income | $78.3M +168.2% | $-114.8M -15.2% | $-99.6M -166.8% | $-37.3M +86.5% | $-275.5M -742.8% | $-32.7M |
| Operating Income | $-36.8M +69.7% | $-121.7M -21.0% | $-100.5M -215.1% | $-31.9M -78.9% | $-17.8M +40.6% | $-30.0M |
| EPS (Diluted) | $1.40 +156.2% | $-2.49 -12.7% | $-2.21 -137.6% | $-0.93 +85.0% | $-6.18 -218.6% | $-1.94 |
| Total Assets | $765.0M +8.7% | $703.5M -26.5% | $957.7M -7.8% | $1.04B -6.7% | $1.11B +101.5% | $552.4M |
| Operating Cash Flow | $-8.6M +47.4% | $-16.3M -2056.3% | $-757.0K +59.1% | $-1.9M -122.8% | $8.1M +154.7% | $-14.9M |
| Free Cash Flow | $-25.0M +25.5% | $-33.6M +15.1% | $-39.5M -65.0% | $-24.0M -52.1% | $-15.8M +33.8% | $-23.8M |
Get alerted when CYRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cryoport, Inc. including:
Top Institutional Holders of CYRX
BlackRock, Inc.
$66.2M4,218,434 shCADIAN CAPITAL MANAGEMENT, LP
$45.9M2,920,681 shMORGAN STANLEY
$35.7M2,276,741 shVANGUARD CAPITAL MANAGEMENT LLC
$33.8M2,151,943 shMILLENNIUM MANAGEMENT LLC
$27.1M1,724,726 shFRED ALGER MANAGEMENT, LLC
$24.3M1,545,293 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$23.3M1,482,500 shGEODE CAPITAL MANAGEMENT, LLC
$20.6M1,312,370 shMAK CAPITAL ONE LLC
$20.1M1,277,359 shFirst Eagle Investment Management, LLC
$20.0M1,271,424 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $66.2M | 4,218,434 |
| CADIAN CAPITAL MANAGEMENT, LP | $45.9M | 2,920,681 |
| MORGAN STANLEY | $35.7M | 2,276,741 |
| VANGUARD CAPITAL MANAGEMENT LLC | $33.8M | 2,151,943 |
| MILLENNIUM MANAGEMENT LLC | $27.1M | 1,724,726 |
| FRED ALGER MANAGEMENT, LLC | $24.3M | 1,545,293 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23.3M | 1,482,500 |
| GEODE CAPITAL MANAGEMENT, LLC | $20.6M | 1,312,370 |
| MAK CAPITAL ONE LLC | $20.1M | 1,277,359 |
| First Eagle Investment Management, LLC | $20.0M | 1,271,424 |
Companies Similar to CYRX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ORTHOPEDIATRICS CORP
Alpha Teknova, Inc.
SHOULDER INNOVATIONS, INC.
SI-BONE, Inc.
Schrodinger, Inc.
Apyx Medical Corp
KORU Medical Systems, Inc.
Twist Bioscience Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CYRX on your watchlist
Track score changes the day Cryoport, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CYRX a good stock to buy?
13F Pro's AI-powered analysis of Cryoport, Inc. (CYRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CYRX are available on the CYRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CYRX is classified as a small company.
Which hedge funds own CYRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CYRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cryoport, Inc.'s investment landscape.